Berman 2010); increased prefrontal glutamate concentrations have been found in a subgroup of schizophrenia patients (Olbrich et al. 2008) . Using post-mortem brain tissue of schizophrenia patients an earlier study did not find changes in the protein expression of mGluR2/3 in the dlPFC (Crook et al. 2002) . A recent study, however, showed a higher expression of mGluR2 than mGluR3 in the dlPFC and a lower expression of mGluR3 in the dlPFC of patients (Ghose et al. 2009 ); receptor binding density, however, has not been studied.
We therefore studied mGluR2/3 density in post-mortem brain tissue of the patient cohort of the schizophrenia research institute (SRI) comprising 37 patients with schizophrenia diagnosis (including 7 schizoaffective patients) and 37 matched controls to identify the potential role of dlPFC mGluR2/3 in schizophrenia.
Methods

1. Post-mortem brain tissue
For the present study, post-mortem brain tissue of the dlPFC (Brodman Area 46) of 37 schizophrenia/schizoaffective patients and 37 matched controls was used. All research was approved and conducted under the guidelines of the Human Research Ethics Committee at the University of Wollongong (HE99.222) and University of New South Wales (HREC 07261). Clinical assessments, selection of cases and matched controls, assessment of tissue quality and preparation of slide-mounted coronal tissue sections (14µm) were performed by the Tissue Resource Centre and the Schizophrenia Research Institute (Weickert et al. 2010) . All experiments and analysis was done blind to the clinical details of each case.
Receptor Autoradiography for mGluR2/3 density
Receptor autoradiography on mGluR2/3 was performed using [ 3 H]LY354740 based on the protocol described previously (Richards et al. 2005) . Two slides per case were pre-incubated for 2 x 10 min in a buffer solution (50mM Tris buffer, 2mM MgCl 2, 2mM CaCl 2; pH=7) at room temperature (RT). Thereafter, the slides were incubated for 60 min at RT in buffer solution containing 50nM [ 
3. Receptor density quantification
Quantification was performed using the Beta-Imager and B vision+ program (BioSpace, France). Cortical regions were analysed according to histological standards (provided by Weickert et al, see Figure 1 ).
Four schizophrenia cases (3 schizophrenia, 1 schizoaffective diagnosis) and 1 control case were excluded from analysis as binding data deviated more than 30% of overall standard deviation.
4. Statistical Analysis
All data was analysed using SPSS (17.0). Data was tested for normality (Lilliefors test) and homogeneity (Levene's test). Student's t-test was used to compare the levels of radioligand binding for schizophrenia/schizoaffective patients vs controls, schizophrenia patients vs controls, schizoaffective patients vs controls, schizoaffective vs schizophrenia patients as well as gender differences and manner of death. Bonferroni correction was used to correct for multiple testing in case of significance. Spearman's correlation was used to test for any effects of continuous descriptive variables including age at death, pH (prefrontal cortex), post mortem interval (PMI), RNA integrity (RIN), freezer storage time, brain weight, brain volume, chlorpromazine equivalent (mg) of lowest, highest, lifetime and last recorded antipsychotic dose, antidepressant treatment, daily ethanol intake, smoking quantity, age of onset and duration of illness on receptor binding (for clinical data see (Weickert et al. 2010) . ANCOVA analysis, controlling for age of death, was performed for obtained significances when using the the Student's t-test; levels of radioligand binding in suicidal vs naturally deceased schizophrenia/schizoaffective patients as well as patients on last recorded high (>450mg/day chlorpromazine equivalent) or low (<450mg/day chlorpromazine equivalent) dose of antipsychotics were therefore studied. Significance was accepted with p < 0.05. Data is presented as mean ± SEM.
Results
Independent of diagnosis, no difference was found between patients and controls in mGluR2/3 receptor density in the dlPFC.
In all groups, schizophrenia patients (R=-0.62; p<0.01), schizoaffective patients (R=-0.92:p<0.01), controls (R=-0.65; p<0.01) and overall cases (R=-0.66; p<0.01), there was a strong negative correlation between mGluR2/3 binding and age at death (Figure 2 ).
In all cases and schizophrenia/schizoaffective patients only, mGluR2/3 binding additional correlated with pH, RIN, time of storage, brain weight, manner of death, antipsychotic dose (as chlorpromazine equivalent), duration of illness and smoking quantity. None of these correlations remained, however, significant after correcting these variables for age at death. The correlation of mGluR2/3 density and age at death remained significant when correcting for any of these variables.
Whereas suicide victims amongst schizophrenia/schizoaffective patients showed higher (17.1 ± 0.5; n=8) mGluR2/3 levels than patients dying from natural death (14.3 ± 0.7; n=26), this was only due to the young age when committing suicide rather than the manner of death (uncorrected F(32,1)=5.99; p<0.05; corrected for age at death F(30,1)=0.70; p=0.41). Similarly, whereas users of (on average in this cohort) low doses of antipsychotics (>450mg/day chlorpromazine equivalent) showed higher levels of mGluR2/3 binding (16.8 ± 0.1; n=13) than users of high doses of antipsychotics (>450mg/day chlorpromazine equivalent) (13.5 ± 0.7; n=16), no significance was given after correction for age at death (uncorrected F(27,1)=7.72; p<0.05; corrected for age at death F(26,1)=2.27; p=0.14).
Discussion
Metabotropic glutamate receptors 2 and 3 have been shown as efficient targets for antipsychotic intervention (Patil et al. 2007 ). We therefore investigated the receptor density of mGluR2/3 in the dlPFC, which has been implicated in the symptomatology of schizophrenia, in patients with schizophrenia/schizoaffective diagnosis and matched control subjects (Figure 1) . No difference in receptor density was found due to schizophrenia/schizoaffective diagnosis (Table 1) . A strong correlation of mGluR2/3 binding density with age at death was found overall and separately for patient and control groups (Figure 2) . No other variables were correlated after correcting for age at death, with and without consideration of DSM-IV diagnosis.
Our data are consistent with previous results, which showed no changes in protein or mRNA expression of mGluR2/3 in the dlPFC of schizophrenia patients compared to controls (Crook et al. 2002; Gupta et al. 2005) . No differences in mGlu2/3R binding levels between schizophrenia or schizoaffective diagnosed patients additionally suggests that this might be common to psychotic illnesses.
We also did not observe any changes correlated to antipsychotic or antidepressant drug treatment. This is in accordance with findings of Gupta et al (2005) and Crook et al (2002) , who neither detected changes in medicated vs unmedicated schizophrenia patients. All studied patient cohorts, including our cohort, showed, however, either variations in treatment history or age at death as a confounding factor so that drug effects cannot be fully excluded. Still, these data are supported by earlier studies on rats, which showed that treatment with haloperidol, clozapine or olanzapine did little or not affect mGluR2/3 expression in the frontal cortex (Tascedda et al. 2001 ).
Age-related reduction in glutamate receptor binding in post-mortem human brain tissues has been demonstrated before (Newell et al. 2005) . Specifically for mGluR2/3 receptors, reduced mRNA and protein expression levels have been shown in healthy controls, however, not schizophrenia patients (Colantuoni et al. 2008; Crook et al. 2002) . This is contrasted by other studies on mGluR2/3, which did not observe age- (2009) showed, however, when, using subtype specific antibodies, a higher expression of mGluR2 than mGluR3 in the dlPFC of healthy controls. In animal studies on mGluR2 and mGluR3 receptor knock-out mice, it was additionally found that mGluR2 rather than mGluR3 mediate the actions of the therapeutically active mGluR2/3 receptor agonist LY379268 (Woolley et al. 2008);  indicating that the mGluR2 is more likely to be involved in the therapeutic efficiency in schizophrenia pathology. We therefore used a protocol favouring binding to mGluR2 over mGluR3 (Richards et al. 2005) . Whereas this confirmed the data of Crook et al (2002), who did not find any differences in mGluR2/3 protein expression, the decrease mGluR3 receptor levels observed by Ghose et al (2009) needs to be confirmed using a more mGluR3 specific protocol or a specific ligand for receptor binding; particularly considering genetic human population studies that suggested that the mGluR3 rather than the mGluR2 are associated with schizophrenia (Harrison and Weinberger 2005).
Our study and studies of others have shown that mGluR2/3 receptors are abundant in the dlPFC, where mGluR2/3 agonists might exhibit their potential to treat schizophrenia symptoms particularly related to cognitive deficits (Crook et al. 2002; Ghose et al. 2009; Gupta et al. 2005) . Though, overall findings to date for expression levels of mGluR2/3 and receptor density of mGluR2/3, with a bias for mGluR2, in the dlPFC showed little or no changes (our results and (Crook et al. 2002; Ghose et al. (2007) showed, however, decreased dimerisation of mGluR3 in Brodmann area 10 of schizophrenic patients while total mGluR3 expression remained unchanged. This indicates that also functional receptor binding for both mGluR2 and mGluR3 and their interaction needs to be explored in schizophrenia patients as well as in response to mGluR2/3 agonist drug treatment before final conclusions can be drawn. On the other hand, considering recent studies on mGluR2 and mGluR3 mutant mice, limbic rather than cortical brain areas might be of relevance to schizophrenia pathology and mGluR2/3 agonist efficiency (Hetzenauer et al. 2008 ).
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Altogether, the mGluR2/3 receptors are a novel and highly promising target for antipsychotic intervention, their way of action, however, remains to be uncovered for a better understanding of their potency to treat schizophrenia. and patients with schizophrenia/schizoaffective diagnosis (SCZ, black diamonds) with the respective age at death. mGluR2/3 was found lower in older subjects independent of schizophrenia diagnosis (R=0.66; p<0.01). Table 1 
